Saturday, January 14, 2023 1:49:35 PM
Anybody who has worked inside a public corporation knows that the management of the corporation cares only about one thing -- their own careers and their own compensation.
Everything else is for show. Companies where management has a big stock-based incentive are better, generally, at doing well for shareholders only because management itself benefits from share value increases.
Corporations suck. Their management usually sucks. They go to the public markets to get capital for their own purposes, and then the second after they have the capital, shareholders are Enemy #1 because they interfere with management's cushy life. Management always hates shareholders -- they see them as annoying rabble.
I guarantee you current AMRN management feel ZERO responsibility for the horrible ride shareholders have been through. They see this company as their own personal vehicle for wealth and success, starting from the very bottom in value. Believe me, they would do a reverse split, dilute the beejeezus out of all of us, reload themselves with tons of cheap equity, and then act as if it were a miracle if some revert-to-the-mean increase in share price got them all rich with no real benefit for us. They could care less about us.
The only counterexample I can think of to this is where a charismatic entrepreneur took a private company to stardom. The entrepreneur sometimes remembers where they came from, and the role that going public had in their own success. Once that entrepreneur moves on and the company falls into the hands of normal corporate management -- that new management hates shareholders.
Everything else is for show. Companies where management has a big stock-based incentive are better, generally, at doing well for shareholders only because management itself benefits from share value increases.
Corporations suck. Their management usually sucks. They go to the public markets to get capital for their own purposes, and then the second after they have the capital, shareholders are Enemy #1 because they interfere with management's cushy life. Management always hates shareholders -- they see them as annoying rabble.
I guarantee you current AMRN management feel ZERO responsibility for the horrible ride shareholders have been through. They see this company as their own personal vehicle for wealth and success, starting from the very bottom in value. Believe me, they would do a reverse split, dilute the beejeezus out of all of us, reload themselves with tons of cheap equity, and then act as if it were a miracle if some revert-to-the-mean increase in share price got them all rich with no real benefit for us. They could care less about us.
The only counterexample I can think of to this is where a charismatic entrepreneur took a private company to stardom. The entrepreneur sometimes remembers where they came from, and the role that going public had in their own success. Once that entrepreneur moves on and the company falls into the hands of normal corporate management -- that new management hates shareholders.
"The biggest obstacles to our progress exist within our own lives in the form of cowardice and the tendency to give up. Breaking through these barriers will unleash a surging wave of change." -- Daisaku Ikeda
Recent AMRN News
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
- New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients • GlobeNewswire Inc. • 11/09/2025 09:15:00 PM
- Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025 • GlobeNewswire Inc. • 11/03/2025 01:30:00 PM
